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Background: Renal primitive neuroectodermal tumor (rPNET) as a member of Ewing’s sarcoma family is extremely
rare and usually occurs in children and young adults. Most literature about rPNET was isolated case reports.
Case presentation: We reported a case of 45-year-old man with the complaint of right flank pain. Computerized
tomography (CT) scan demonstrated a large substantive tumor involving the lower pole of the right kidney. Then
the patient underwent radical nephrectomy. Pathologic characteristics and immunohistochemical analysis
confirmed the diagnosis of rPNET. Additionally, the patient received three cycles of chemotherapy, and was still
alive without metastasis at 15-months follow-up.
Conclusion: rPNET is rare and presents aggressive clinical behavior and worse prognosis. We expect that further
awareness and study of this rare tumor can be had by presenting our case.
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Primitive neuroectodermal tumor (PNET) composed of
small uniform round cells, is characterized by a trans-
location resulting in a fusion transcript of the EWS gene
and ETS-related family of oncogenes [1]. PNET is pre-
sumed to be derived from neural crest, mostly present-
ing as bone or soft tissue masses in the trunk or axial
skeleton in children and young adults [2]. Because of the
morphologic overlap and the same genetic aberrations
with Ewing’s sarcoma, PNET is now considered virtually
the same entity as Ewing’s sarcoma [3]. Renal PNET
(rPNET) as a member of Ewing’s sarcoma family is ex-
tremely rare [4]. Most literature about rPNET was iso-
lated case reports. Recently, a case of 45-year-old man
with rPNET was treated and followed up by us. Here we
report this case and review the literature.
Case presentation
A 45-year-old man with the complaint of right flank
pain for 1 week was admitted in August 2010. Ultraso-
nography showed a very large tumor on the right kidney.* Correspondence: tongshijun@hotmail.com
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reproduction in any medium, provided the orComputerized tomography (CT) scan showed a 12×10×10
cm substantive tumor involving the lower pole of the right
kidney, while in the enhanced phase the tumor presented
inhomogenous contrast enhancement with focal cystic
and necrotic areas (Figure 1A). Urine examination showed
occult blood (3+) and other laboratory examinations
were normal. Chest X-ray and abdominal ultrasono-
graphy showed no evidence of tumor metastasis. Phy-
sical examination indicated a large and firm mass in
the right abdomen.
The preoperative diagnosis of the patient was right
renal carcinoma and radical nephrectomy was immedi-
ately done. The whole procedure was successful and the
right kidney with the tumor was integratedly resected
(Figure 1B). After slitting the specimen, a white sizable
tumor measuring 13×13×9 cm with interspersed areas of
hemorrhage and necrosis replacing the lower pole of the
right kidney could be seen (Figure 1C).
The microscopic examination revealed that the tumor
was composed of monotonous round cells with hyperchro-
matic round nucleus. The interspersed small dark cells indi-
cating pyknosis of the tumor cells could form rosette-like
structures (Figure 2A). The cytoplasm of the tumor cells
was scanty, but, the rim of clear cytoplasm and discrete cell
membranes were often apparent without extensive degene-
rative changes. Additionally, there were some small tumor. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The image and gross appearance of rPNET. (A) CT scan of the kidney demonstrated a 12×10×10 cm substantive tumor involving
the lower pole of the right kidney, then, after administration of the contrast medium, the tumor showed inhomogenous contrast enhancement
with focal cystic and necrotic areas. (B) The substantive tumor measuring 13×13×9 cm replacing the lower pole of the right kidney was
integratedly resected. (C) After slitting the specimen, a white sizable tumor with interspersed areas of hemorrhage and necrosis could be seen
(arrow: the upper pole of the right kidney).
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was negative. Most importantly, immunohistochemical
staining indicated the positive expression of CD99, S-100,
and neuron-specific enolase (NSE) in the tumor cells which
supported the diagnosis of rPNET (Figure 2C, D, E).Figure 2 HE and immunohistochemical staining of rPNET. (A) The rose
The tumor cells showed strong positive expression of CD99. (C) The tumor
showed positive expression of NSE.The patient then underwent three cycles of chemo-
therapy (one cycle every 3 weeks). The chemothera-
peutic agents included ifosfamide (2g, days 1 to 3) and
epirubicin (100 mg, day 1). After the 15-months follow-
up, the patient was still alive without metastasis.tte-like structures formed by the small monotonous round cells. (B)
cells showed positive expression of S-100. (D) The part of tumor cells
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rPNET first described by Mor et al. in 1975 is a very rare
and aggressive malignant tumor [4]. rPNET usually
occurs in children and young adults. Boys and men are
more likely to suffer rPNET and the sex ratio (male:
female) is about 3:1 [2]. The tumors tend to be very
large and the maximum diameter of rPNET is always
>10 cm [5-7]. So far, most literature about rPNET
was isolated case reports and the largest case series
including 79 patients with rPNET was described by
Parham et al. in 2001 [8]. The age of these patients
ranged from 2 months to 73 years old with a median
age of 20 years [8].
The presenting symptoms and images of rPNET are
non-specific and similar to other renal tumors. There-
fore it is often difficult to distinguish rPNET from renal
cell carcinoma and Wilm’s tumor [9]. However the
images of rPNET are useful for staging of the disease.
The diagnosis of rPNET mainly depends on pathologic
characteristics and biomarkers. rPNET is characterized
by small uniform round cells with dark nuclei, ill-
defined cytoplasmic borders, and poorly-formed rosette-
like structures [1,8]. Immunohistochemical staining of
rPNET is always positive for different neural biomarkers
such as S-100, Leu 7(HNK-1), and particularly NSE [4].
Additionally, CD99 also named MIC-2 antigen is crucial
in the diagnosis of rPNET and the positive expression of
CD99 has been demonstrated in more than 90% of
rPNET [5]. But, CD99 is not specific and cannot be used
as an absolute biomarker [10].
PENT is characterized by a translocation resulting in a
fusion transcript of the EWS gene and ETS-related fami-
ly of oncogenes [1]. Cytogenetic analyses may therefore
be helpful in the diagnosis of rPENT. The translocation
of t(11:22) (q24:q12) with the fusion transcript between
the EWS gene (22q12) and the ETS-related oncogene
(11q24) have been detected in more than 90% of theTable 1 The combination therapy of surgery and chemothera
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No Nephrec
chemotrPNET [5]. Several studies applied preoperative fine nee-
dle aspiration cytology to diagnose rPNET based on the
constellation of cytomorphologic and immunohisto-
chemical findings with subsequent confirmation by cyto-
genetic analyses [11-13].
rPNET appears to be an unique clinical entity that
behaves more aggressively than PNET arising at other
sites [6]. Approximately 20% to 50% of patients present
with distant metastases, most commonly to regional
lymph nodes, bone, bone marrow, lung, and liver [2].
The 5-year disease-free survival rate of rPNET is about
45% to 55% [4]. The overall survival in patients who had
localized rPENT was longer than that in the patients
who had rPENT with regional nodes or distant metasta-
ses [14]. The preferred treatment for rPENT is surgical
resection associated with chemotherapy and radiother-
apy treatment. The role of radiotherapy is not clear, but
it may be advocated in locally advanced disease and in-
volvement of Gerota’s fascia [14]. Postoperative chemo-
therapy for rPENT is usually used and can improve the
prognosis of rPNET [6]. Most cases of rPNET may recur
after nephrectomy without adjuvant chemotherapy. Severe
multiple liver metastases occurred 6 months after radical
nephrectomy in a 21-year-old man with rPENT who im-
mediately underwent six cycles of chemotherapy with ifos-
famide, etoposide, and adriamycin. After this treatment,
residual tumor was removed and the tumor cells were ab-
sent histologically [6]. The most commonly used che-
motherapeutics are adriamycin, etoposide, dactinomycin,
vincristine, cyclophosphamide, and ifosfamide [4-7]. Se-
veral studies about combination therapy of surgery and
chemotherapy for rPENT are summarized in Table 1.
This case presented with a relatively large localized
tumor and had non-specific symptoms. Radical nephrec-
tomy was immediately done based on the findings of CT
of the right kidney. In this case, both the pathologic char-
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rPNET. By reviewing the literature, the importance of
combination therapy for rPENT was known. The patient
underwent three cycles of chemotherapy including ifosfa-
mide and epirubicin. After the 15-months follow-up, the
patient was still alive without metastasis. Therefore, we
suggest that postoperative adjuvant chemotherapy should
be performed in cases of rPNET.
Conclusion
rPNET is rare and presents with aggressive clinical beha-
vior and worse prognosis. Immunohistochemical staining
for CD99 and some neural biomarkers along with cyto-
genetic studies play a great role in the diagnosis of rPNET.
Radical nephrectomy combined with chemotherapy and
radiotherapy is the recommended treatment for rPENT.
We expect that further awareness of this rare tumor can
be had by presenting our case.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Series Editor of this journal.
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